Novartis to acquire Excellergy for up to $2B, advancing next-gen allergy treatment Exl-111.

Novartis announced an agreement to acquire Excellergy, Inc., a biotech company developing Exl-111, a next-generation anti-IgE antibody in Phase 1 trials. This acquisition strengthens Novartis' allergy portfolio by adding a therapy designed to provide faster, deeper suppression of IgE signaling, potentially improving symptom control and convenience for allergic diseases. The deal could cost up to $2 billion and is expected to close in the second half of 2026, pending regulatory approvals. This move aligns with Novartis' strategy to innovate in immunology and expand treatment options for IgE-driven conditions like food allergy and asthma.